✦ LIBER ✦

Re-charging the costs of R&D: when is it appropriate?

✍ Scribed by N. H. Aked; R. D. Reader

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Chemotherapy in the Last Two Weeks of Li

✍ Eric Prommer; Sydney Dy; Lynn Billing; Mary Buss; Thomas Smith 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Preoperative Embolization of Carotid Bod

✍ Virginia R. Litle; Linda M. Reilly; Tammy K. Ramos 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 560 KB

Is the Current Accounting Treatment of E

✍ James R. Frederickson; Elizabeth Webster; Ian O. Williamson 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB

The cost of biopharmaceutical R&D: is bi

✍ Joseph A. DiMasi; Henry G. Grabowski 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 160 KB

Count the Value of R&D, Not Just Its Cos

✍ Yeager, K.E. 📂 Article 📅 1996 🏛 IEEE 🌐 English ⚖ 577 KB

Conservative treatment of adenocarcinoma

✍ S. Vinker; A. Shani; M. Open; E. Fenig; R. Dgani 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 147 KB